Back to Mobile View

effient

More than a year after AstraZeneca filed for approval, the FDA will make its decision on Thursday. A large study showed the blood thinner worked better than Plavix for treating acute coronary syndrome -- but approval isn't a sure thing, due in part to some oddities in the study's results.
Several recent studies of drugs used to treat and prevent strokes appear to favor AstraZeneca's (AZN) Brilinta and Eli-Lilly's (LLY) Effient over Plavix. Plavix, co-marketed by Bristol-Myers Squibb (BMY) and Sanofi-Aventis (SNY), is the second best-selling drug in the world.
Pharmaceutical giant Eli Lilly -- maker of Prozac and Cialis -- is expected to post solid fourth-quarter profits on Thursday after a recent restructuring. But the results will likely be lower than the year-ago quarter.

Market Movers

SymbolLastChange / %Volume

Most Actives

BAC
Bank of America Corp
8.09-0.10
-1.16%
144.54M
ALU
Alcatel-Lucent (ADR)
2.19+0.25
+12.63%
92.86M
PBR
Petroleo Brasileiro S.A. (ADR)
29.64-2.35
-7.35%
23.01M
GE
General Electric Company
18.82-0.32
-1.65%
22.24M

% Gainers

CIE
Cobalt International Energy
32.67 +8.77
+36.69%
11.64M
LNKD
LinkedIn Corp.
89.23 +12.84
+16.81%
7.21M
ALU
Alcatel-Lucent (ADR)
2.19 +0.25
+12.63%
92.86M
WNS
WNS (Holdings) Limited (ADR)
10.56 +1.16
+12.34%
2.63M

% Losers

NBG-A
National Bank of Greece SA (ADR)
5.74-1.01
-14.96%
72,615
KV-A
K V Pharmaceutical Co. Class A
2.22-0.39
-14.94%
914,345
OSG
Overseas Shipholding Group, Inc.
10.26-1.57
-13.27%
1.16M
KV-B
K-V Pharmaceutical Co. Class B
2.29-0.34
-12.93%
2,179
Newswire

Follow Us

Headlines From DailyFinance Partners

CNN Money
CNBC
Smart Money
Consumer Reports
Huffington Post
AOL Energy
AOL Jobs
Business News Personal Finance Investing Our Partners

DailyFinance Sitemap | Terms of Service | Privacy Policy | Trademarks | HELP | Advertise With Us

© Copyright 2012 AOL Inc. All Rights Reserved